Investigational Drug Information for CC-220

What is the development status for investigational drug CC-220?

CC-220 is an investigational drug.

There have been 22 clinical trials for CC-220. The most recent clinical trial was a Phase 2 trial, which was initiated on November 12^th 2021.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.

There are twenty-nine US patents protecting this investigational drug and two hundred and sixty-six international patents.

Summary for CC-220

US Patents	29
International Patents	266
US Patent Applications	127
WIPO Patent Applications	75
Japanese Patent Applications	21
Clinical Trial Progress	Phase 2 (2021-11-12)
Vendors	24

Recent Clinical Trials for CC-220

Title	Sponsor	Phase
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study	National Cancer Institute (NCI)	Phase 1/Phase 2
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study	Mayo Clinic	Phase 1/Phase 2
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma	Bristol-Myers Squibb	Phase 1/Phase 2

See all CC-220 clinical trials

Clinical Trial Summary for CC-220

Top disease conditions for CC-220

Top clinical trial sponsors for CC-220

See all CC-220 clinical trials

US Patents for CC-220

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
CC-220		Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies	Celgene Corporation (Summit, NJ)
CC-220		Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione	Celgene Corporation (Summit, NJ)
CC-220		Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast	Celgene Corporation (Summit, NJ)
CC-220		Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same	Celgene Corporation (Summit, NJ)
CC-220		3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus	Celgene Corporation (Summit, NJ)

International Patents for CC-220

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
CC-220	Australia	AU2015305449	2034-08-22
CC-220	Australia	AU2021209158	2034-08-22
CC-220	Brazil	BR112017003620	2034-08-22
CC-220	Canada	CA2958867	2034-08-22
CC-220	Chile	CL2017000416	2034-08-22